Jounce Therapeutics Stock Revenue
| JNCEDelisted Stock | USD 1.88 0.00 0.00% |
Jounce Therapeutics fundamentals help investors to digest information that contributes to Jounce Therapeutics' financial success or failures. It also enables traders to predict the movement of Jounce Stock. The fundamental analysis module provides a way to measure Jounce Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jounce Therapeutics stock.
Jounce |
Jounce Therapeutics Company Revenue Analysis
Jounce Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Jounce Therapeutics Revenue | 82 M |
Most of Jounce Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jounce Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Jounce Therapeutics reported 82 M of revenue. This is 98.92% lower than that of the Biotechnology sector and 88.96% lower than that of the Health Care industry. The revenue for all United States stocks is 99.13% higher than that of the company.
Jounce Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jounce Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jounce Therapeutics could also be used in its relative valuation, which is a method of valuing Jounce Therapeutics by comparing valuation metrics of similar companies.Jounce Therapeutics is currently under evaluation in revenue category among related companies.
Jounce Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | (82.09 M) | |||
| Shares Outstanding | 52.64 M | |||
| Shares Owned By Insiders | 15.99 % | |||
| Shares Owned By Institutions | 85.33 % | |||
| Number Of Shares Shorted | 2.02 M | |||
| Price To Earning | 10.76 X | |||
| Price To Book | 0.27 X | |||
| Price To Sales | 7.27 X | |||
| Revenue | 82 M | |||
| Gross Profit | 27.2 M | |||
| EBITDA | (50.16 M) | |||
| Net Income | (50.92 M) | |||
| Cash And Equivalents | 148.56 M | |||
| Cash Per Share | 2.87 X | |||
| Total Debt | 11.89 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 6.78 X | |||
| Book Value Per Share | 3.54 X | |||
| Cash Flow From Operations | (28.88 M) | |||
| Short Ratio | 0.48 X | |||
| Earnings Per Share | (0.96) X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 141 | |||
| Beta | 0.75 | |||
| Market Capitalization | 101.59 M | |||
| Total Asset | 212.55 M | |||
| Retained Earnings | (292.79 M) | |||
| Working Capital | 173.66 M | |||
| Current Asset | 103.95 M | |||
| Current Liabilities | 51.26 M | |||
| Z Score | 3.78 | |||
| Net Asset | 212.55 M |
About Jounce Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jounce Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jounce Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jounce Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Jounce Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Jounce Therapeutics' short interest history, or implied volatility extrapolated from Jounce Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Jounce Therapeutics information on this page should be used as a complementary analysis to other Jounce Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |